Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
-
CDT Announces Canadian Patent for AZD5904 in Male Infertility
-
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
-
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
-
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
-
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
-
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
-
CDT Equity Inc. Announces Reverse Stock Split
-
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
-
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth